Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
.
A cGAS-dependent response links DNA damage and senescence in alveolar epithelial cells: A potential drug target in IPF.
.